---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-063125"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2026-06-01T10:20:20+00:00"
generated_at: "2026-06-01T10:25:22.727663+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# MoonLake Immunotherapeutics signs commercial supply and capacity agreements with Vetter for sonelokimab

## Summary
- Master Commercial Supply Agreement signed May 22, 2026 with Vetter for manufacturing pre-filled application systems.
- Capacity Agreement commits MoonLake to binding annual minimum and maximum quantity orders; failure may trigger compensation.
- Agreements include pricing adjustment provisions based on Vetter’s cost increases and change-of-control termination rights.
- Sonelokimab is MoonLake’s key product candidate; deal supports potential commercialization.

## SEC filing metadata
- accession: 0001213900-26-063125
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2026-06-01T10:20:20+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000121390026063125/0001213900-26-063125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000121390026063125/ea0292693-8k_moonlake.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-063125
- JSON: https://secwatch.observer/filing/0001213900-26-063125.json
- Plain text: https://secwatch.observer/filing/0001213900-26-063125.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.